NCT07272837

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: University of Alberta · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected. * Have blood levels assessed through two finger pricks. * Complete three days of food records.

Conditions

• Type 2 Diabetes
• Obesity
• Semaglutide

Timeline

• Start date: 2026-04-01
• Primary completion: 2027-12-31
• Completion: 2028-04-30
• First posted: 2025-12-09
• Last updated: 2026-03-13